Consistent with their mission to prioritize clinical convenience, practicality, and effectiveness, numerous considerations were incorporated into the design of their product lines. From the packaging, to the shape configurations, all relate to optimizing suitability for use and potential for clinical benefit. But, FIRST AND FOREMOST, its products were developed with design requirements for safety, and products provided for distribution are verified to satisfy these requirements.
What sets Seed Biotech apart is its process. They use precise methods to get measurable results and create better biologic products. Their proprietary decellularization process demonstrates a greater than 95% reduction in DNA.
Under the guidance of clinical and industry experienced experts, Seed Biotech’s core competency is based on a novel decellularization and stabilization process conducted in a quality by-design facility with advanced operational support systems.
Seed Biotech is uniquely able to optimally prepare highly variable biological materials through a dynamic purification process that depletes biomaterials of cells and cellular contents without imparting unintentional alterations to the extracellular matrix comprised of soluble and non-soluble bioactive constituents. This technology uniquely positions Seed Biotech as an industry leader in innovation and a manufacturer of high-quality products.
ADJECTIVE: Denoting, relating to, or involving tissues or cells that are genetically dissimilar and hence immunologically incompatible, although from individuals of the same species.
About:
With strategic offices located in Atlanta, Georgia, and the greater Reno, Nevada area, Allogeneic Solutions is perfectly positioned to support medical professionals nationwide with acellular amniotic membrane allografts from Seed Biotech, Inc.
As a dedicated HCT/P distributor, we deeply value the relationships between manufacturers and providers. Our unwavering commitment to quality compelled us to undertake extensive due diligence, culminating in our partnership with Seed Biotech, Inc. A trailblazer headquartered in Chattanooga, Tennessee, Seed Biotech is committed to pioneering advanced research, development, production, distribution, and the efficacious application of intelligently designed biological material-based products.
Regenerative Medicine
Regenerative human cellular and tissue products, a category within human cellular and tissue-based products, refer to treatments that utilize living cells or tissues from humans to replace or repair damaged or diseased body parts. The FDA also refers to these products as human cellular and tissue-based products or (HCT/Ps).
The FDA has established comprehensive industry standards to monitor and regulate tissue transplant products, including stem cells, to ensure maximum patient safety. Cellular and tissue products that adhere to FDA-defined criteria are not classified as drugs but as HCT/P 361 products. While these products are FDA-regulated, they are not FDA-approved. When conducting HCT/P provider due diligence prioritize organizations that have not warranted written interaction with the FDA.
and their associated logos are Trademarks or Registered Trademarks of Seed Biotech, Inc.
RingBack Request
